Skip to main content
Top
Published in: Health and Quality of Life Outcomes 1/2005

Open Access 01-12-2005 | Research

Cross-cultural validation and analysis of responsiveness of the QUALIOST®: QUAlity of Life questionnaire In OSTeoporosis

Authors: Christine de la Loge, Kate Sullivan, Robert Pinkney, Patrick Marquis, Christian Roux, Pierre Jean Meunier

Published in: Health and Quality of Life Outcomes | Issue 1/2005

Login to get access

Abstract

Background

The QUALIOST® was designed for use with the SF-36 to measure established osteoporosis-specific quality of life (QoL). The reliability (internal consistency and test-retest) and validity of the questionnaire were established in a stand-alone psychometric validation study. The objective of this paper is to provide additional information on the instrument's responsiveness using clinical trial data, along with the reliability and validity of translated versions.

Methods

The Spinal Osteoporosis Therapeutic Intervention (SOTI) was an international clinical trial comparing strontium ranelate to placebo on the occurrence of new vertebral fracture in patients with postmenopausal osteoporosis. QoL was a secondary endpoint, assessed using the SF-36 and QUALIOST® at baseline and every six months, with the main analysis at 3-year follow-up. Questionnaire acceptability, analysis of the hypothesised structure, internal consistency reliability and responsiveness to clinical change over time were assessed at the 3-year follow up.

Results

1592 patients from 11 countries completed at least one QoL questionnaire. The psychometric properties of the questionnaires were assessed on cross-sectional (N = 1486) and longitudinal (N = 1288) data. Item discriminant validity of the QUALIOST® was excellent, as was item convergent validity, with 100% of item-scale correlations being above the 0.40 level. Internal consistency reliability was also extremely good, with high Cronbach's alpha scores above the 0.70 benchmark. Responsiveness results were consistent for all QUALIOST® scores, indicating that greater decreases in QoL corresponded to greater numbers of fractures experienced. QUALIOST® scores also differed according to the type of fracture suffered. This was demonstrated by increased effect sizes for more severe vertebral fractures (clinical vertebral and painful vertebral). In comparing responsiveness, the QUALIOST® scores were generally more consistent than those of the SF-36. Most notably, the QUALIOST® was more responsive with regard to painful vertebral fractures than the SF-36.

Conclusion

The QUALIOST® is a reliable and valid tool for measuring QoL in postmenopausal osteoporotic women. Being available in several validated language versions, it is ready to be used in a variety of settings, including international clinical trials.
Appendix
Available only for authorised users
Literature
1.
go back to reference Gold DT: The clinical impact of vertebral fractures: quality of life in women with osteoporosis. Bone 1996, 18: 185S-189S. 10.1016/8756-3282(95)00500-5PubMedCrossRef Gold DT: The clinical impact of vertebral fractures: quality of life in women with osteoporosis. Bone 1996, 18: 185S-189S. 10.1016/8756-3282(95)00500-5PubMedCrossRef
2.
go back to reference Genant HK, Wu CY, van Kuijk C, Nevitt MC: Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 1993,8(9):1137–1148.PubMedCrossRef Genant HK, Wu CY, van Kuijk C, Nevitt MC: Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 1993,8(9):1137–1148.PubMedCrossRef
3.
go back to reference Measuring quality of life in women with osteoporosis. Osteoporosis Quality of Life Study Group Osteoporos Int 1997, 7: 478–487. Measuring quality of life in women with osteoporosis. Osteoporosis Quality of Life Study Group Osteoporos Int 1997, 7: 478–487.
4.
go back to reference Helmes E: Function and disability or quality of life? Issues illustrated by the Osteoporosis Functional Disability Questionnaire (OFDQ). Qual Life Res 2000, 9: 755–761. 10.1023/A:1008930007855CrossRef Helmes E: Function and disability or quality of life? Issues illustrated by the Osteoporosis Functional Disability Questionnaire (OFDQ). Qual Life Res 2000, 9: 755–761. 10.1023/A:1008930007855CrossRef
5.
go back to reference Acquadro C, Jambon B, Ellis D, Marquis P: Languages and translation issues. In Quality of Life and Pharmacoeconomics in clinical trials. second edition. Edited by: Spilker B. Philadelphia: PA: Lippincott-Raven publishers; 1996:575–585. Acquadro C, Jambon B, Ellis D, Marquis P: Languages and translation issues. In Quality of Life and Pharmacoeconomics in clinical trials. second edition. Edited by: Spilker B. Philadelphia: PA: Lippincott-Raven publishers; 1996:575–585.
6.
go back to reference Marquis P, Cialdella P, de la Loge C: Development and validation of a specific quality of life module in post-menopausal women with osteoporosis: The QUALIOST. Qual Life Res 2001, 10: 555–566. 10.1023/A:1013041206433PubMedCrossRef Marquis P, Cialdella P, de la Loge C: Development and validation of a specific quality of life module in post-menopausal women with osteoporosis: The QUALIOST. Qual Life Res 2001, 10: 555–566. 10.1023/A:1013041206433PubMedCrossRef
7.
go back to reference Meunier PJ, Roux C, Ortolani S, Badurski J, Kaufman JM, Spector T, Diez-Perez A, Seeman E, Leemel E, Balogh A, Pors-Nielsen S, Phenekos C, Rizzoli R, Slosman D, Tupinon-Mathieu I, Reginster JY: Strontium ranelate reduces the vertebral fracture risk in women with postmenopausal osteoporosis. Osteoporos Int 2002, 13: 520–522. 10.1007/s001980200065CrossRef Meunier PJ, Roux C, Ortolani S, Badurski J, Kaufman JM, Spector T, Diez-Perez A, Seeman E, Leemel E, Balogh A, Pors-Nielsen S, Phenekos C, Rizzoli R, Slosman D, Tupinon-Mathieu I, Reginster JY: Strontium ranelate reduces the vertebral fracture risk in women with postmenopausal osteoporosis. Osteoporos Int 2002, 13: 520–522. 10.1007/s001980200065CrossRef
8.
go back to reference Ware JE, Snow KK, Kosinski M, Gandek B: SF-36 health survey manual and interpretation guide. Boston, MA: The Health Institute, New England Medical Center; 1993. Ware JE, Snow KK, Kosinski M, Gandek B: SF-36 health survey manual and interpretation guide. Boston, MA: The Health Institute, New England Medical Center; 1993.
9.
go back to reference Ware JE, Kosinski MK, Keller SD: SF-36 Physical and Mental Health Summary scales: a user's manual. The Health Institute, New England Medical Center, Boston, Massachussets; 1994. Ware JE, Kosinski MK, Keller SD: SF-36 Physical and Mental Health Summary scales: a user's manual. The Health Institute, New England Medical Center, Boston, Massachussets; 1994.
10.
go back to reference Campbell DT, Fisk DW: Convergent and discriminant validation by the multitrait multi-method matrix. Psychol Bull 1959, 56: 85–105.CrossRef Campbell DT, Fisk DW: Convergent and discriminant validation by the multitrait multi-method matrix. Psychol Bull 1959, 56: 85–105.CrossRef
11.
go back to reference Nunnally JC: Psychometric theory. second edition. McGraw-Hill New York; 1978. Nunnally JC: Psychometric theory. second edition. McGraw-Hill New York; 1978.
12.
go back to reference Deyo RA, Dierh P, Patrick D: Reproducibility and responsiveness of health status measures statistics and strategies for evaluation. Control Clin Trials 1991, 12: 142–158.CrossRef Deyo RA, Dierh P, Patrick D: Reproducibility and responsiveness of health status measures statistics and strategies for evaluation. Control Clin Trials 1991, 12: 142–158.CrossRef
13.
go back to reference Cohen J: Statistical Power Analysis for the Behavioral Sciences. second edition. Lawrence Erlbaum Associates Publishers; 1998. Cohen J: Statistical Power Analysis for the Behavioral Sciences. second edition. Lawrence Erlbaum Associates Publishers; 1998.
14.
go back to reference Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, Cannata J, Balogh A, Lemmel EM, Pors-Nielsen , Rizzoli R, Genant HK, Reginster JY: The effects of strontium ranelate on the risk of vertebral fractures in women with postmenopausal osteoporosis. N Engl J Med 2004, 350: 459–468. 10.1056/NEJMoa022436PubMedCrossRef Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, Cannata J, Balogh A, Lemmel EM, Pors-Nielsen , Rizzoli R, Genant HK, Reginster JY: The effects of strontium ranelate on the risk of vertebral fractures in women with postmenopausal osteoporosis. N Engl J Med 2004, 350: 459–468. 10.1056/NEJMoa022436PubMedCrossRef
15.
go back to reference Chassany O, Sagnier P, Marquis P, Fullerton S, Aaronson N, for the ERIQA group: Patient-reported outcomes: the examples of health-related quality of life – A European guidance document for the improved integration of health-related quality of life assessment in the drug regulatory process. Drug Inf J 2002, 36: 209–238.CrossRef Chassany O, Sagnier P, Marquis P, Fullerton S, Aaronson N, for the ERIQA group: Patient-reported outcomes: the examples of health-related quality of life – A European guidance document for the improved integration of health-related quality of life assessment in the drug regulatory process. Drug Inf J 2002, 36: 209–238.CrossRef
16.
go back to reference Lips P, Cooper C, Agnusdei D, Caulin F, Egger P, Johnell O, Kanis JA, Liberman U, Minne H, Reeve J, Reginster JY, de Vernejoul MC, Wiklund I: Quality of life as outcome in the treatment of osteoporosis: the development of a questionnaire for quality of life by the European Foundation for Osteoporosis. Osteoporos Int 1997, 7: 36–38. 10.1007/BF01623457PubMedCrossRef Lips P, Cooper C, Agnusdei D, Caulin F, Egger P, Johnell O, Kanis JA, Liberman U, Minne H, Reeve J, Reginster JY, de Vernejoul MC, Wiklund I: Quality of life as outcome in the treatment of osteoporosis: the development of a questionnaire for quality of life by the European Foundation for Osteoporosis. Osteoporos Int 1997, 7: 36–38. 10.1007/BF01623457PubMedCrossRef
17.
go back to reference Tosteson ANA, Hammond CS: Quality-of-life assessment in osteoporosis, health status and preferenced-based measures. Pharmacoeconomics 2002, 20: 289–303.PubMedCrossRef Tosteson ANA, Hammond CS: Quality-of-life assessment in osteoporosis, health status and preferenced-based measures. Pharmacoeconomics 2002, 20: 289–303.PubMedCrossRef
18.
go back to reference Oleksik AM, Ewing SK, Duong T, Shen W, Lips S: Three years of health related quality of life assessment in postmenopausal women with osteoporosis: impact of incident vertebral fractures, age and severe adverse events. J Bone Miner Res 2000, 15: 1118. Oleksik AM, Ewing SK, Duong T, Shen W, Lips S: Three years of health related quality of life assessment in postmenopausal women with osteoporosis: impact of incident vertebral fractures, age and severe adverse events. J Bone Miner Res 2000, 15: 1118.
19.
go back to reference Silverman SL, Minshall ME, Shen W, Harper KD, Xie S, Health-Related Quality of Life Subgroup of the Multiple Outcomes of Raloxifene Evaluation Study: The relationship of health-related quality of life to prevalent and incident vertebral fractures in postmenopausal women with osteoporosis. Arthritis Rheum 2001, 44: 2611–2619. Publisher Full Text 10.1002/1529-0131(200111)44:11<2611::AID-ART441>3.0.CO;2-NPubMedCrossRef Silverman SL, Minshall ME, Shen W, Harper KD, Xie S, Health-Related Quality of Life Subgroup of the Multiple Outcomes of Raloxifene Evaluation Study: The relationship of health-related quality of life to prevalent and incident vertebral fractures in postmenopausal women with osteoporosis. Arthritis Rheum 2001, 44: 2611–2619. Publisher Full Text 10.1002/1529-0131(200111)44:11<2611::AID-ART441>3.0.CO;2-NPubMedCrossRef
Metadata
Title
Cross-cultural validation and analysis of responsiveness of the QUALIOST®: QUAlity of Life questionnaire In OSTeoporosis
Authors
Christine de la Loge
Kate Sullivan
Robert Pinkney
Patrick Marquis
Christian Roux
Pierre Jean Meunier
Publication date
01-12-2005
Publisher
BioMed Central
Published in
Health and Quality of Life Outcomes / Issue 1/2005
Electronic ISSN: 1477-7525
DOI
https://doi.org/10.1186/1477-7525-3-69

Other articles of this Issue 1/2005

Health and Quality of Life Outcomes 1/2005 Go to the issue